Stay updated with breaking news from Nasdaq Stro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tekla Capital Management LLC trimmed its stake in shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) by 10.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 147,531 shares of the company’s stock after selling 16,393 shares during the quarter. Tekla Capital Management LLC’s holdings in Sutro Biopharma were worth $1,192,000 at the end […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. Earnings and Valuation This table compares Sutro Biopharma and […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Moderna (NASDAQ:MRNA – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Insider & Institutional Ownership 87.6% of Sutro Biopharma shares are owned […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Brookline Capital Acquisition (NASDAQ:BCAC – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Valuation & Earnings This table compares Sutro Biopharma […]
Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) have received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month […]